Managing the microbiological quality of pharmaceutical excipients

PDA Journal of Pharmaceutical Science and Technology

Volumn 59, Issue 6, 2005, Pages 381-395

  Cundell, Anthony M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACACIA EXTRACT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; EXCIPIENT; GELATIN; GLYCEROL; HYDROXYPROPYLCELLULOSE; LACTOSE; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; NON PRESCRIPTION DRUG; PHOSPHORIC ACID DERIVATIVE; PLANT EXTRACT; POVIDONE; SODIUM PEROXIDE; STARCH; STARCH GLYCOLATE SODIUM; STEARIC ACID; SUCROSE; TALC; UNCLASSIFIED DRUG; XANTHAN;

ACACIA; ARTICLE; BACTERIAL COUNT; BACTERIUM CONTAMINATION; COLONY FORMING UNIT; DRUG CAPSULE; DRUG COATING; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; GOOD MANUFACTURING PRACTICE; METHODOLOGY; MICROBIAL COLONIZATION; MOULD; QUALITY CONTROL; RISK ASSESSMENT; TABLET MANUFACTURE; YEAST;

CONSUMER PRODUCT SAFETY; DRUG CONTAMINATION; DRUG INDUSTRY; EXCIPIENTS; INDUSTRIAL MICROBIOLOGY; QUALITY CONTROL; RISK ASSESSMENT;

EID: 30344440690     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. International Pharmaceutical Excipients Council of the Americas Website - Frequency Asked Questions; www.ipecamericas.org/public/faqs.htmls.
2. Ermens, H. Pharmaceuticals Excipients - The Past and Future. Business Briefing: Pharmagenerics, 2004; www.ipec.org/news/jul2001.pdf.
3. Corn Refiners Association; www.corn.org/web/cahist-l.htm.
4. Hanna, S. A. Quality Assurance. In Pharmaceutical Dosage Forms: Tablets, 2nd edition; Lieberman, H. A.; Lachman, L.; Schwartz, J. B, Eds.; Marcel Dekker, Inc.: New York, 1990; Volume 3, pp 497-553.
5. Mathieuu, M. P., Ed.; Murphy, W. J., Contributing Ed. New Drug Development: A Regulatory Overview; OMEC International, Inc.: Washington, D.C.; 1987, pp 93-95.
6. Guideline For Submitting Supporting Documentation. In Drug Applications for the Manufacture of Drug Products; Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, February 1987.
7. FDA Drug Master Files-Excipient Listings, www. fda.gov/cder/dmf.
8. USP 28/NF23 Magnesium Sulfate, NF Monograph, 2005.
9. Russell, R. Synthetic excipients challenge all-natural organics. Pharm. Tech. 29 (4) April 2004, 38-50.
10. th Edition R.C. Rowe, P. J. Sheskey and P. J. Weller (Editors) Handbook of Pharmaceutical Excipients. American Pharmaceutical Association: Washington, DC 2003.
11. FDA Guide to Inspections of Bulk Pharmaceutical Chemicals, May 1994.
12. Handel, T. Quality Agreements Contract Pharma October 2002.
13. Payne, D. N. Microbial ecology of the production process In Guide to Microbiological Control in Pharmaceutical; Denyer, S.; Baird, R., Eds.; Ellis Horwood: London, 1990; pp 53-67.
14. Tang, S. Microbial limits reviewed: The basis for unique Australian regulatory requirements for microbiological quality of non-sterile pharmaceuticals. PDA J. Pharm. Sci Technol. 1998, 52 (3), 100-1009.
15. Montgomery, E. R.; Manu-Tawiah, W. Microbiological considerations when selecting excipients during product development. Am. Pharm. Rev. 2004, 7 (4), 34-39.
16. Bacon, C. W.; Hinton, D. M. Isolation and Culture of Endophytic Bacteria and Fungi. In Manual of Environmental Microbiology; Hurst, C. J.; Knudsen, G. R.; Mclnerney, M. J.; Stetzenbach, L. A.; Walter, M. V., Eds.; ASM Press: Washington, DC, 1997 ; pp 413-421.
17. Cundell, A. M. 2001 Comparison of microbiological testing practices in clinical, food, water and pharmaceutical microbiology in relation to the microbiological attributes of nutritional and dietary supplements. Pharm. Forum 28 (3), 964-985.
18. Fishman, J. A.; Rubin R. H. Infection in organ-transplant recipients. New England Journal of Medicine 1998, 338 (24), 1741-1751.
19. 1997 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus.
20. De Veau, I.; Dabbah, R.; Sutton, S. The USP perspective to minimize the potential risk of TSE infectivity in bovine-derived articles used in the manufacture of medical products. Pharm. Forum 2004, 30(5), 1911-1921.
21. th Edition R.C. Rowe, P. J. Sheskey and P. J. Weller (Editors) Handbook of Pharmaceutical Excipients. American Pharmaceutical Association: Washington, DC 2003; pp 354-357.
22. Friedel R. R.; Cundell, A. M. The application of water activity measurements to the microbiological attributes of non-sterile OTC drug products. Pharm. Forum 1998, 24 (2), 6087-6090.